Potential Use of Lu 177 Vipivotide Tetraxetan in Non-VISION Prostate Cancer Settings

TLX007-CDx, if approved by the FDA, has the potential to become a new PSMA PET imaging agent for prostate cancer.

Adam Weiner, MD, discusses his journey toward becoming an oncologist with a focus in urology in this episode of Emerging Experts.

BNT324/DB-1311 gained fast track designation from the FDA in unresectable advanced or metastatic castration-resistant prostate cancer who have progressed after standard treatments.

In season 5, episode 1 of Targeted Talks, Badrinath Konety, MD, delves into the critical topic of prostate cancer screening and discusses some of the recent advancements in the prostate cancer space.

The tissue-based companion diagnostic device was approved for the same therapy and indication in August 2023.

Five-year follow-up from the IMpower010 trial shows atezolizumab improves overall survival vs BSC in resected stage IB-IIIA NSCLC.